BofA downgraded Candel Therapeutics (CADL) to Neutral from Buy with a $7 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Carl June to Research Advisory Board
- Candel Therapeutics Extends Lease Agreement in Needham
- Candel Therapeutics Advances with Promising Cancer Therapies
- Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential